“DFD-03 (0.1% Tazarotene), Twice-daily, Short-Contact Lotion Formulation, Showed Similar Pharmacokinetic Exposure to the Marketed Cream Product with Once-Daily Overnight Application”, J of Skin, vol. 1, no. 3.1, p. s46, Oct. 2017, doi: 10.25251/skin.1.supp.45.